Dr Reddy's Laboratories on Thursday said it has joined hands with global biotech firm Alvotech to co-develop and commercialise a biosimilar product for treating multiple types of cancer.
The Hyderabad-based drug major has entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets, Dr Reddy's Laboratories said in a statement.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
Keytruda (pembrolizumab) is indicated for the treatment of numerous cancer types.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
In 2024, worldwide sales of Keytruda were $29.5 billion.
The collaboration combines Dr Reddy's and Alvotech's proven capabilities in biosimilars thereby speeding up the development process and extending the global reach for this biosimilar candidate, the company noted.
Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, it stated.
Subject to certain exceptions, each party will have the right to commercialize the product globally, it added.
"Oncology has been a top focus therapy area for us and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology," Dr Reddy's CEO Erez Israeli said.
Alvotech chairman and CEO Robert Wessman said the agreement demonstrates Alvotech's ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of its pipeline by pursuing growing global markets.
"It further enables us to increase the availability of cost-effective, critical biologic medications to patients world-wide," he added.
Dr Reddy's shares were trading 3.49% up at Rs 1,295.80 apiece on BSE.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
.jpg?im=FeatureCrop,algorithm=dnn,width=350,height=197)
